secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001193125-23-075734
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update
--------------------------------------------------------------------------------

- Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
- Securities purchase agreement with Nantahala Capital, Abingworth, and Vivo Capital for up to $60 million in gross proceeds.
- Cash and cash equivalents of $14.6 million as of December 31, 2022.
- Net loss of $5.5 million for Q4 2022, compared to $2.8 million in Q4 2021.
- R&D expenses were $3.8 million for Q4 2022, compared to $3.7 million in Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/d380040d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-075734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer